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Summary 
Aim. The aim this pilot study of the all-Polish multicenter TRES-DEP (Treatment Resistant Depression) 
project was the detection and analysis of bipolar spectrum features in drug-resistant (DR) patients with 
unipolar depression in comparison with patients who responded to standard antidepressant treatment and 
remitted (non-drug-resistant-non-DR). 
Method. Fifty DR patients (group 1) and 50 non-DR patients (group 2), aged 18-65 years, fulfilling ICD-
10 / DSM-IV criteria for depressive episode or recurrent depressive disorder, were included in the study. 
The presence of bipolar spectrum (BS) was detected by the Mood Disorder Questionnaire (MDQ) and the 
Hypomania Checklist Scale (HCL-32).  
Results. There were statistically significantly more patients fulfilling BS criteria as assessed with MDQ or 
HCL-32 in group 1 than in group 2 (44% vs 12%, p < 0.001 and 62% vs 34%, p < 0.005 respectively). Sig-
nificantly more DR patients, compared to non-DR patients, considered their last remission as partial (88% 
vs 52%, p = 0.001).  Non-DR patients had a history of fewer depressive episodes (5.1 ± 3.8 vs 8.5 ± 5.0; 
p = 0.001) and reported a longer time since the last hospitalization (41.9 ± 17.1 vs 14.8 ± 26.5 months, 
p< 0.005). More DR patients fulfilling MDQ BS criteria (MDQ(+)) compared to DR patients without bipolar 
spectrum considered the last remission as partial or reported lack of remission (100% vs 21%; p < 0.05) 
or reported treatment nonadherence (41 vs 18%, p = 0.055). More MDQ(+) DR patients had occurrences 
of suicide attempts (41% vs 18%, p = 0.055) and a mean number of suicide attempts was higher in this 
group (0.86 ± 1.28 vs 0.25 ± 0.59; p < 0.05). 
Conclusion. The results of the study suggest that misdiagnosed and inadequately treated bipolarity may 
be one of the main reasons for non-response in the treatment of depression with antidepressant drugs. 
bipolar disorder / drug-resistant depression, bipolar spectrum / Mood Disorder Questionnaire / 
Hypomania Check list-32
INTRODUCTION
A growing body of evidence suggests that 
undiagnosed and therefore inadequately treat-
ed bipolarity may be one of the most impor-
tant causes of drug resistance in depression di-
agnosed as unipolar. The results of the Polish 
multicenter DEP-BI study showed that a sig-
nificant majority of patients treated for either 
a depressive episode or recurrent depressive 
disorder present different forms of bipolar dis-
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order (BD) [1, 2]. Such patients were more of-
ten drug resistant. [3]. Other trials have also 
revealed bipolar features in drug-resistant de-
pressive patients [4, 5, 6, 7]. The need for fur-
ther and more detailed research into this prob-
lem was the basis for the multicenter all-Polish 
Treatment Resistant Depression Project (TRES-
DEP). The main aim of TRES-DEP was analysis 
of the bipolar features in a group of drug resis-
tant patients  with unipolar depression in com-
parison to depressive patients who respond-
ed to standard antidepressant treatment and 
remitted. The demographic and clinical char-
acteristics of the drug-resistant patient group 
was also described. 
The following paper presents the pilot re-
sults of the TRES-DEP project. 
MATERIAl AND METHODS
Fifty drug-resistant (group 1) and 50 non-
drug-resistant (group 2, control group) pa-
tients, aged 18-65 years fulfilling ICD-10 /
DSM-IV criteria for depressive episode or re-
current depressive disorder were included in 
the study. The main exclusion criteria were: 
treatment with mood stabilizers, the diagno-
sis of substance misuse, dementia, and the di-
agnosis of severe neurological or somatic dis-
ease. Patients who scored > 18 points on the 
Hamilton Depression Rating Scale were also 
not included in the study in order avoid the 
risk of false negative results in bipolar detec-
tion tools due to severe depressive state. Pa-
tients were interviewed using clinical and so-
ciodemographic questionnaires. The severi-
ty of depressive symptoms was measured by 
the 17-item Hamilton Depression Rating Scale 
(HDRS-17) [8, 9, 10]. Bipolar features were de-
tected using the Mood Disorder Questionnaire 
(MDQ, by Hirschfeld et al) [11, 12] as well as 
the Hypomania Check-List (HCL-32, by Angst 
et al) [13]. 
Drug-resistance was defined as a lack of sig-
nificant clinical improvement after at least 
two treatment trials with antidepressants ap-
plied through a suitable period of time (min. 4 
weeks) and in suitable doses [14, 15]. Group 2 
(gr. 2, N = 50) consisted of patients who did not 
show drug-resistance in previous depressive 
episodes and who achieved symptomatic and 
clinical remission during the last or current de-
pressive episode (< 7 points in HDRS17). 
Presence of the bipolar spectrum detected by 
MDQ was defined as at least 7 positive (“yes”) 
answers in the first part of the MDQ including 
13 questions concerning manic / hypomanic 
symptoms plus the occurrence of at least two 
of them in the same period of the patient’s life 
as well as any moderate or serious problems 
which these symptoms cause for the patient 
[11, 12]. The HCL-32 bipolar spectrum criteri-
on used in the study was 14 or more positive 
answers (“yes”) [13]. 
The statistical analysis of the quantitative 
data was examined with descriptive statistics 
(median, mean, standard deviation) and box-
plots. If the normality and equality of variance 
assumptions were present (Shapiro-Wilk test), 
a t-test was performed. If the assumptions 
were not met, a non-parametric test was used 
(Mann Whitney U test or Wilcoxon rank-sum 
test). The chi2 test was performed for the anal-
ysis of qualitative differences between groups. 
A p value of < 0.05 was considered statistically 
significant [16, 17, 18].
RESUlTS
1. Sociodemographic characteristics
The mean age (±  SD) in the drug resistant 
group was significantly higher than in con-
trol group. There were no significant differ-
ences in the male/female ratio between group 
1 (1/4) and group 2 (6/19), (Chi2 test) in addi-
tion to there being no other statistically signif-
icant differences between the groups accord-
ing to sociodemographic parameters /variables 
such as: marital state, number of children, edu-
cation level, or occupational status (Tab. 1).
2. Clinical characteristics (disease course, current 
depression episode)
Taking into account the course of the disease, 
patients in group 1 were ill for an average of 
10.7 ± 7.7 years, while patients in group 2 for 
8.5 ± 6.7 of years  but the difference was statis-
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tically not significant. The age at the onset of 
the illness in both groups wasn’t significantly 
different. Moreover, in both groups the num-
ber of patients with early onset of disease (be-
fore 25) was similar (Tab. 2). 
The average number of previous episodes of 
depression was significantly larger in the treat-
ment resistant than in the control group. There 
were no statistically significant differences be-








Age 49.0± 7.5 45.4 ± 9.6 0.037
Number of children 1.7 ± 1.2 1.4 ± 1.1 NS
Chi2-Test
Sex
M n = 10 (20%)
F n = 40 (80%)
M n = 12 (24%)
F n = 38 (76%)
NS
Marital status
Yes n = 37 (74%)
No n = 13 (26%)
Yes n = 0 (60%)















Working n = 18 (36%) n = 20 (40%) NS
Pension n = 25 (50%) n = 2 0 (40%) NS
Table 1. Selected sociodemographic data in groups 1 and 2
hospitalized individuals (as reported during 
interview) and the average number of hospi-
talizations. However, the time since the last 
hospitalization was significantly longer in the 
group of non drug-resistant patients in com-
parison to the drug-resistant patient group. Pa-
tients from group 1 more frequently estimated 
their last remission as incomplete. There were 
no significant differences between groups in 
different aspects of compliance, i.e. unauthor-
ized discontinuation of treatment or modifica-
tion of doses. The groups did not differ statisti-
cally in the number of suicide attempts or ide-
ations in the history as well as in comorbidity 
with somatic illness (Tab. 2). 
Patients from group 2 more frequently re-
ported a lack of family history of mental disor-
ders than treatment-resistant patients (group 
1). Family history of depression, schizophrenia, 
anxiety disorders, suicides, and BD did not dif-
ferentiate between the groups. BD occurrence 
in the family was reported by only one per-
son in group 1 and one in group 2. However, a 
family burden of alcohol abuse was statistical-
ly more frequent in the drug-resistant patient 
group  than in the control group (Tab. 2).
The duration of the current depressive episode 
was statistically longer in the treatment –resistant 
group (group 1) than in the group 2 (Tab. 3). 
There were no significant differences be-
tween groups in frequency of occurrence of 
suicidal thoughts and suicidal tendencies dur-
ing the course of the episodes (Tab. 3).
3. Occurrence of bipolar features in studied groups
In the drug-resistant patient group (group 1), 
the MDQ bipolar spectrum criteria were ful-
filled by significantly more individuals than in 
the non-drug-resistant group (group 2) . Among 
the drug-resistant patients, too, more individuals 
fulfilled the bipolar features criteria by the HCL-
32 in comparison to the drug-resistant patients. 
Similarly, applying the criteria of both tests si-
multaneously, the number of patients with bi-
polar spectrum features was significantly great-
er in group 1  than in group 2. ( Tab. 4) 
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Table 2. Selected clinical data regarding the course of the illness in groups 1 an 2
Table 3. Selected clinical data regarding the current depression episode in groups 1 and 2 of the illness in groups 1 an 2
Table 4. Bipolar features – number of people fulfilling bipolar MDQ or HCL-32 criteria in groups 1 and 2. (MDQ (+)/HCL (+) 
– subgroups of patients, whose results in MDQ and HCL respectively indicated presence of bipolar features.  MH (+)  





Gr 1 vs Gr 2
p
t-Test
Time since the beginning of illness (years) 10.7 ± 7.7 8.5 ± 6.7 NS
Age at onset of illness 38.4 ± 8.5 36.9 ± 10.0 NS
Number of episodes 8.5 ± 5.0 5.1 ± 3.8 0.001
Number of hospitalizations 2.3 ± 2.8 1.5 ± 1.6 NS
Months since the last hospitalization 14.8 ± 26.5 41.9 ± 71.1 0.003
Number of suicide attempts 0.52 ± 1.0 0.46 ± 1.0 NS
Chi2-test
Suicide attempts in the past n = 14 (28%) n = 13 (26%) NS
last remission
Full 12% (n = 6)
Incomplete 88% 
(n = 44)




Irregularity of treatment n = 14 (28%) n = 12 (24%) NS
Family history of depression n = 18 (36%) n = 12 (24%) NS
Family history of alcoholism n = 12 (24%) n = 4 (8%) 0.029





Gr 1 vs Gr 2
p
t-Test
Duration of episode (in weeks) 13 ± 8.7 7.6 ± 3.3 0.001
Number of treatments 2.34 ± 0.6 1.0 ± 0 0.001
Chi2-Test
Presence of suicidal thoughts n = 29 (58%) n = 22 (42%) NS










n = 22 (44%)
n = 28 (56%)
n =  6 (12%)
n = 44 (88%) < 0.001
HCl (+)
HCl (-)
n = 31 (62%)
n = 19 (38%)
n = 17 (34%)
n = 33 (66%) 0.005
MH (+)
MH (-)
n = 19 (38%)
n = 31 (62%)
n =  5  (10%)
n = 45 (90%) = 0.001
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4. Bipolar features – characteristics of answers  
in MDQ and HCl
The next step was the analysis of answers 
to the individual questions in the MDQ and 
HCL questionnaires. In the first 13-ques-
tion part of the MDQ, drug-resistant patients 
(gr. 1) answered “yes” onto following questions 
(Q) statistically significantly more frequently 
in comparison to the non drug-resistant group 
(gr. 2) : Q1 : “…you felt so good or so hyper 
that other people thought you were not your 
normal self or you were so hyper that you got 
into trouble ? (p = 0.002, Chi2 test), Q3 : “...you 
felt much more self-confident than usual?” 
(p = 0.002, Chi2 test), Q5 : “...you were much 
more talkative or spoke much faster than usu-
al?” (p = 0.025 ; Chi2 test)”, Q8 : ”...you had 
much more energy than usual?” (p = 0.008 ; 
Chi2 test), Q9 : “...you were much more ac-
tive or did many more things than usual?” 
(p = 0.001, Chi2 test), Q11: “...you were much 
more interested in sex than usual ?” (p = 0.010 ; 
Chi2 test).
In the HCL-32, among 32 questions from the 
mania/hypomania symptoms list, statistically 
significantly more answered “yes” in group 1 
in comparison to group 2 on three questions : Q5 : 
“I am more sociable (make more phone calls, 
go out more)” (p = 0.009, Chi2 test), Q16 : “I am 
more interested in sex, and/or have increased 
sexual desire” (p = 0.005, Chi2 test), Q21 : “I am 
more easily distracted” (p = 0.020, Chi2 test).
5. Clinical and demographic characteristics  
of patients with drug-resistant depression
There were no statistically significant differ-
ences regarding age, sex, marital state, number 
of children, education level, and occupational 
status between drug-resistant patients fulfill-
ing and not-fulfilling the bipolar spectrum cri-
teria by MDQ or  HCL-32 (Tab. 5 and 6).
Table 5. Bipolar features according to MDQ criteria – selected sociodemographic data regarding the course of treatment  





Age 49.0 ± 7.2 49.0 ± 7.8 NS





n =  6 (27.3%)
n = 16 (72.7%)
n = 4 (14.3%)
n = 24 (85.7%)
NS
NS






n =  5 (22.7%)
n =  2 (9.1%)
n =  9 (40.9%)
n =  6 (27.3%)
n = 2 (7.1%)
n = 3 (10.7%)
n = 15 (53.6%)





Working n =  9 (40.9%) n = 9 (32.1%) NS
Pension n =  9 (40.9%) n = 16 (57.1%) NS
There were also no statistically significant 
differences in a range of such factors character-
izing course of the illness as: age at the onset of 
disease, average number of episodes and hos-
pitalizations, average time since the last hos-
pitalization (Tab. 7 and 8). 
Similarly, family history of depression, al-
cohol abuse, bipolar disorder, schizophrenia, 
anxiety disorders, suicides and coexistence of 
somatic diseases did not differentiate drug-re-
sistant patients presenting or not presenting 
bipolar spectrum features (Tab. 7 and 8).
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Moreover, there were no differences in select-
ed clinical data regarding the current depres-
sion episode i.e.: duration of  episode, number 
of administrated treatments, presence of sui-
cidal thoughts or tendencies (Tab. 9 and 10).
It should be emphasized that drug-resis-
tant patients fulfilling the MDQ bipolar fea-
tures criteria estimated their last remission as 
incomplete and reported non-compliance re-
flected by irregularities in treatment and dos-
ing non-adherence significantly more often 
than non-bipolar spectrum patients. More-
over, in drug-resistant bipolar spectrum pa-
tients in comparison with patients not fulfill-
ing the MDQ criteria, there was a statistically 
significant greater number of suicide attempt-
ers and a greater average number of suicide at-
tempts (Tab. 7).
Table 6.  Bipolar features according to HCL criteria – selected sociodemographic data regarding the course of treatment  





Age 48.4 ± 8.5 50.0 ± 5.4 NS





n = 6 (19.4%)
n = 25 (80.6%)
n = 4 (21.1%)
n = 15 (78.9%)
NS
NS






n =  5 (16.1%)
n =  3 (9.7%)
n = 14 (45.2%)
n = 9 (29.0%)
n = 2 (10.5%)
n = 2 (10.5%)
n = 10 (52.6%)





Working n = 12 (38.7%) n = 6 (31.6%) NS
Pension n = 15 (48.4%) n = 10 (52.6%) NS
Table 7. Selected clinical data regarding the course of the illness in drug resistant patients (group 1) fulfilling (MDQ(+))  









Time since the beginning of illness (years) 9.9 ± 7.6 11.2 ± 9.8 NS
Age at onset of illness 39.1 ± 9.4 37.8 ± 7.9 NS
Number of episodes 8.0 ± 4.4 6.0 ± 4.6 NS
Number of hospitalizations 2.0 ± 2.4 2.5 ± 3.1 NS
Months since the last hospitalization 13.2 ± 19.2 15.4 ± 31.0 NS
Number of suicide attempts 0.86 ± 1.28 0.25 ± 0.59 0.029
Chi2-Test
last remission
    Full
n = 0 (0%)
Incomplete
n = 22 (100%)
     Full
(n = 6) 21%
Incomplete
n = 22 (79%)
0.021
Irregularities of treatment n = 9 (41%) n =  (18%) (0.055)
Suicide attempts in the past n = 9 (41%) n = 5 (18%) (0.055)
Family history of depression n = 9 (41%) n = 9 (32%) NS
Family history of alcoholism n = 6 (27%) n = 6 (21%) NS
Negative family history of mental disorders n = 9 (41%) n = 13 (46%) NS
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Table 8. Selected clinical data regarding the course of the illness in drug resistant patients (group 1) fulfilling (HCL (+))  









Time since the beginning of illness (years) 10.9 ± 8.7 10.2 ± 6.0 NS
Age at onset of illness 37.5 ± 9.4 39.8 ± 6.9 NS
Number of episodes 6.8  ± 4.2 6.4 ± 5.0 NS
Number of hospitalizations 2.2  ± 2.4 2.6 ± 3.4 NS
Months since the last hospitalization 15.2 ± 21.7 14.1 ± 34.2 NS
Number of suicide attempts 0.71 ± 1.16 0.21 ± 0.54 NS
Test Chi2
Last remission
    Full
n = 2 (6%)
Partial
n = 29 (94%)
   Full
n = 4 (21%)
Partial
n = 15 (79%)
NS
Irregularities of treatment n = 10 (32%) n = 4 (21%) NS
Suicide attempts in the past n = 11 (36%) n = 3 (16%) NS
Family history of depression n = 13 (42%) n = 5 (26%) NS
Family history of alcoholism n = 7 (23%) n = 5 (26%) NS
Negative family history of mental disorders n = 12 (39%) n = 10 (53%) NS
Table 9. Selected clinical data regarding the current depression episode in drug resistant patients (group 1) fulfilling (MDQ (+)) 
or not fulfilling MDQ (MDQ(-)) bipolar spectrum criteria
MDQ(+) MDQ(-) MDQ(+) vs MDQ(-)
t-Test
Duration of episode (in weeks) 11 ± 5.7 14.5 ± 10.2 NS
Number of treatments 2.18 ± 0.5 2.46 ± 0.7 NS
Chi2-Test
Presence of suicidal thoughts n = 11 (50%) n = 18 (64.3%) NS
Presence of suicidal tendencies n = 5 (22.7%) n = 5 (17.9%) NS
Table 10. Selected clinical data regarding the current depression episode in drug resistant patients (group 1) fulfilling (HCL(+)) 
or not fulfilling (HCL(-)) HCL-32 bipolar spectrum criteria
MDQ(+) MDQ(-) MDQ(+) vs MDQ(-)
t-Test
Duration of episode (in weeks) 11 ± 5.7 14.5 ± 10.2 NS
Number of treatments 2.18 ± 0.5 2.46 ± 0.7 NS
Chi2-Test
Presence of suicidal thoughts n = 11 (50%) n = 18 (64.3%) NS
Presence of suicidal tendencies n = 5 (22.7%) n = 5 (17.9%) NS
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DISCUSSION
The group of drug-resistant patients, in com-
parison with non-drug-resistant patients, was 
characterized by a shorter time since the last 
hospitalization and a larger number of epi-
sodes, as well as a larger number of individu-
als who subjectively estimated their last remis-
sion to be incomplete. These data reflect the 
unfavourable pattern of the course of depres-
sive disorder in the case of drug resistance.
In the group of drug-resistant patients, there 
were significantly more persons with a family 
history of different mental disorders (depres-
sion, alcoholism, schizophrenia, bipolar dis-
order, anxiety disorders). However, it should 
be pointed that in both groups, only 2% of pa-
tients reported cases of bipolar disorder in 
the family. Such an extremely low percentage 
suggests the underdiagnosis of BD. Attention 
should be paid to the statistically more fre-
quent occurrence of alcohol abuse in the fam-
ilies of drug-resistant patients, which may be 
a confirmation of undiagnosed bipolarity. Ac-
cording to Sonne et al [19], alcohol abuse coex-
ists with BD in about 33% of cases and maybe 
a factor suggesting incidence of bipolar spec-
trum in depressive disorder. It seems that use 
of the questions included in such tools as the 
MDQ or the HCL, not only for the examina-
tion of the patient, but also during a family in-
terview may improve the detection of bipolar-
ity among patients’ relatives.
In the drug resistant group, in comparison to 
the non-drug-resistant group there were sig-
nificantly more patients fulfilling MDQ and/
or HCL-32 bipolar spectrum criteria. This sug-
gests that a significant percentage of refracto-
ry depression is represented by misdiagnosed 
and therefore inadequately treated bipolar dis-
order. Such data are consistent with the re-
sults of previous investigations. Sharma at al 
[6] found the presence of BD (mainly type II) 
or features of broadly-defined bipolarity re-
spectively in 59% and 80% of patients treat-
ed for drug-resistant depression. In another 
study, characterized by long-term follow-up 
(1-7 years), it was observed that a significant 
part of drug-resistant depression is associated 
with BD. The diagnosis was changed from uni-
polar affective disorder to bipolar disorder in 5 
of 21 patients [7]. The results of the all-Polish, 
multicenter DEP-BI project showed that about 
60% of the outpatients treated by psychiatrists 
for recurrent depression or depressive episode 
represent different forms of BD [1, 3]. More-
over, in a group of patients who fulfilled bipo-
larity criteria there were more cases of drug-
resistance [3].
The differences between drug-resistant and 
non drug-resistant patients in frequency of 
answer to specific questions in the MDQ and 
HCL questionnaires shown in this pilot study 
also suggest that, in case of adding of a larger 
number of patients to the trial, it may be possi-
ble to choose such specific questions from the 
questionnaires used, which would be used 
during interviewing patients to increase the 
probability of recognition of bipolar features 
among drug-resistant patients. The varying, 
in terms of occurrence or lack of it, features of 
bipolarity in the group of drug-resistant pa-
tients, characterized by answers to questions 
from the MDQ and HCL questionnaires, may 
enable the separation of factors which, during 
the interview, may contribute to an improve-
ment in diagnostic vigilance in the future. 
Drug-resistant patients fulfilling the MDQ 
bipolar spectrum criteria, compared to the 
drug-resistant patients without bipolar spec-
trum, considered the last remission as partial 
or reported lack of remission, reported treat-
ment nonadherence, had more frequent occur-
rences of suicide attempts as well as a great-
er number of suicide attempts. These results 
suggest that presence of bipolar spectrum may 
significantly and negatively affect the course 
and prognosis in drug-resistant depression. 
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